Aids in the diagnosis of Celiac disease. 

The HLA DQ Association test provides genotyping for detection of HLA-DQ2 (DQA1*05:01 or 05:05 and DQB1*02:01 or 02:02) and HLA-DQ8 (DQB1*03:02). Patients with DQ2, half DQ2 and/or DQ8 are predisposed to celiac disease. A negative result essentially rules out celiac disease. In addition to DQ2 and DQ8 status, the report also includes complete DQA and DQB genotypes, homozygosity for DQB1*02, and genetic risk assessment.

Lavender (EDTA), 10mL

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

Lavender (EDTA), 10mL

Hospital clients submitting a request for this assay on a patient with Medicare must complete and submit a Molecular Medical Billing request form along wit the sample.

Molecular Medicare billing request

• Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
• All information requested is required in order for your request to be completed

Ambient

• Incorrect specimen container (tube type)
• Yellow-top (ACD) tube

Polymerase chain reaction (PCR)/sequence-specific oligonucleotide probes (Luminex®). This is a class II antigen level and an allele level test.

An interpretive report will be included

Celiac disease is an autoimmune disorder characterized by a well defined genetic predisposition and sensitivity to gluten (found in wheat, barley and rye) that causes inflammation in the small intestine, villous atrophy, and malabsorption.

Celiac disease can present with gastrointestinal symptoms and/or widely variable non- gastrointestinal findings such as iron deficiency anemia, dermatitis herpetiformis, osteoporosis, chronic fatigue, short stature, neurologic symptoms, and many more. Gastrointestinal symptoms are present in fewer than 50% of cases of systematic celiac disease. Strict avoidance of gluten in the diet will rid inflammation in most cases, and celiac-associated antibodies are likely to disappear with time.

Celiac disease affects approximately 1% of the US population, but only about 17% of cases are currently diagnosed. Underdiagnosis is likely due to the variable presentation of celiac disease and clinical overlap with numerous other disorders such as IBS. The prevalence of celiac disease in increased in certain autoimmune disorders such as insulin-dependent diabetes(~6%),thyroiditis (~2-4%) and Sjogren syndrome (~5%). It is also increased in Down syndrome (5-12%), Turner syndrome (~3%), Williams syndrome (3-10%) and selective IgA deficiency (~2-10%).

Genetic predisposition to celiac disease requires the presence of specific variants of the human leukocyte antigen (HLA) class II genes HLA-DQA1 and HLA-DQB1 to be present. These genes encode the alpha and beta chains of the celiac-associated proteins DQ2 and DQ8. Presence of DQ2, half DQ2 and/or DQ8 is required but not sufficient for the development of celiac disease. One or more of these HLA results are present in 30% of the population byt overall, only 3% of these individuals develop celiac disease. The risk for developing celiac disease increases when there is a first degree relative with celiac disease (eg. the risk approaches 40% for sibs with the same HLA genotype as a patient with celiac disease).

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.

• Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
• All information requested is required in order for your request to be completed

Molecular Medicare billing request